Advanced BioMedical Technologies (OTCMKTS:ABMT – Get Free Report) and Heart Test Laboratories (NASDAQ:HSCS – Get Free Report) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their risk, valuation, dividends, analyst recommendations, profitability, institutional ownership and earnings.
Profitability
This table compares Advanced BioMedical Technologies and Heart Test Laboratories’ net margins, return on equity and return on assets.
Net Margins | Return on Equity | Return on Assets | |
Advanced BioMedical Technologies | N/A | N/A | N/A |
Heart Test Laboratories | N/A | -144.12% | -94.48% |
Valuation & Earnings
This table compares Advanced BioMedical Technologies and Heart Test Laboratories”s top-line revenue, earnings per share (EPS) and valuation.
Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
Advanced BioMedical Technologies | $270,000.00 | 0.16 | -$510,000.00 | N/A | N/A |
Heart Test Laboratories | $14,700.00 | 226.67 | -$6.61 million | ($7.91) | -0.43 |
Volatility and Risk
Advanced BioMedical Technologies has a beta of -0.11, suggesting that its share price is 111% less volatile than the S&P 500. Comparatively, Heart Test Laboratories has a beta of 2.9, suggesting that its share price is 190% more volatile than the S&P 500.
Analyst Ratings
This is a summary of recent ratings and recommmendations for Advanced BioMedical Technologies and Heart Test Laboratories, as provided by MarketBeat.com.
Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
Advanced BioMedical Technologies | 0 | 0 | 0 | 0 | 0.00 |
Heart Test Laboratories | 0 | 0 | 2 | 0 | 3.00 |
Heart Test Laboratories has a consensus price target of $13.50, indicating a potential upside of 297.06%. Given Heart Test Laboratories’ stronger consensus rating and higher possible upside, analysts clearly believe Heart Test Laboratories is more favorable than Advanced BioMedical Technologies.
Insider & Institutional Ownership
17.2% of Heart Test Laboratories shares are owned by institutional investors. 34.1% of Advanced BioMedical Technologies shares are owned by company insiders. Comparatively, 1.8% of Heart Test Laboratories shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.
Summary
Heart Test Laboratories beats Advanced BioMedical Technologies on 6 of the 11 factors compared between the two stocks.
About Advanced BioMedical Technologies
Advanced Biomedical Technologies, Inc., a development stage company, designs, develops, manufactures, and markets biomaterial internal fixation devices. It offers polymer osteosynthesis devices, such as surgical screws, binding wires, rods, and related medical devices for the treatment of orthopedic trauma, sports-related medical treatment, cartilage repair, and related treatments, as well as for reconstructive dental procedures. The company was formerly known as Geostar Mineral Corporation and changed its name to Advanced Biomedical Technologies, Inc. in March 2009. Advanced Biomedical Technologies, Inc. was founded in 2002 and is based in New York, New York.
About Heart Test Laboratories
Heart Test Laboratories, Inc., a medical technology company, provides cardiovascular diagnostic devices. The company offers MyoVista wavECG, a resting 12-lead electrocardiograph (ECG) to provide diagnostic information related to cardiac dysfunction, as well as conventional ECG information. It serves clinics, doctor's offices, urgent care centers, and hospitals. The company was incorporated in 2007 and is headquartered in Southlake, Texas.
Receive News & Ratings for Advanced BioMedical Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Advanced BioMedical Technologies and related companies with MarketBeat.com's FREE daily email newsletter.